FREQUENCY OF MRSA BACTEREMIA IN CANCER PATIENTS
DOI:
https://doi.org/10.71000/q4kh2w03Keywords:
Bacteremia, Cancer Patients, Chemotherapy, , Methicillin-Resistant Staphylococcus aureus, Oncology, Pakistan, RadiotherapyAbstract
Background: Methicillin-resistant Staphylococcus aureus (MRSA) is a major pathogen responsible for bloodstream infections, particularly in immunocompromised individuals such as cancer patients. Due to their immunosuppressive therapies, prolonged hospital exposures, and frequent invasive procedures, oncology patients remain highly vulnerable to MRSA bacteremia. Early identification and management of these infections are essential to reducing morbidity, hospital stay, and overall mortality. In Pakistan, data on MRSA prevalence in the cancer population remain limited, necessitating localized research.
Objective: To assess the frequency of Methicillin-resistant Staphylococcus aureus (MRSA) infections primarily in the bloodstream of cancer patients in a tertiary care setting in Pakistan.
Methods: This cross-sectional study was conducted in the Department of Medicine, Shaukat Khanum Memorial Cancer Hospital, Lahore, from July 12, 2024, to January 12, 2025. A total of 115 cancer patients aged 19 to 60 years were enrolled through consecutive non-probability sampling from the outpatient department. Inclusion criteria included diagnosed cancer patients not currently on antibiotics or with other known bacterial infections. Blood samples were aseptically collected and cultured to identify MRSA. Data were recorded using a structured proforma and analyzed in SPSS version 25.0. Descriptive statistics were calculated, and MRSA prevalence was determined.
Results: The mean age of participants was 41.27 ± 11.34 years, with 65 (56.5%) males and 50 (43.5%) females. Among the participants, MRSA was confirmed in 60 (52.2%) patients. Cancer types included blood (13.9%), liver (15.6%), head and neck (18.3%), brain (11.3%), colon (13.0%), pancreatic (11.3%), and other cancers (16.5%). Regarding treatment, 42 (36.5%) were receiving chemotherapy, 44 (38.3%) radiotherapy, and 29 (25.2%) both modalities.
Conclusion: The study identified a notably high prevalence of MRSA bacteremia in cancer patients, emphasizing the urgent need for early detection, preventive strategies, and timely initiation of targeted antibiotic therapy to reduce complications and disease progression.
References
Valentine JC, Hall L, Verspoor KM, Gillespie E, Worth LJ. Use of a Victorian statewide surveillance programme to evaluate the burden of healthcare-associated Staphylococcus aureus bacteraemia and Clostridioides difficile infection in patients with cancer. Intern Med J. 2022;52(7):1215-24.
Pichtchoulin S, Selmeryd I, Freyhult E, Hedberg P, Selmeryd J. Staphylococcus aureus bacteremia and cardiac implantable electronic devices in a county hospital setting: a population-based retrospective cohort study. Ups J Med Sci. 2021;126.
Li Z, Zhuang H, Wang G, Wang H, Dong Y. Prevalence, predictors, and mortality of bloodstream infections due to methicillin-resistant Staphylococcus aureus in patients with malignancy: systemic review and meta-analysis. BMC Infect Dis. 2021;21(1):74.
Lopera C, Monzó P, Aiello TF, Chumbita M, Peyrony O, Gallardo-Pizarro A, et al. Prevalence and impact of multidrug-resistant bacteria in solid cancer patients with bloodstream infection: a 25-year trend analysis. Microbiol Spectr. 2024;12(10):e0296123.
Allen PB, Goyal S, Switchenko J, Tarabadkar E, Pouch S, Parikh P, et al. Mitigation strategies among cutaneous T-cell lymphoma patients with positive Staphylococcus aureus skin and soft tissue cultures have unclear impacts on the risk of subsequent bacteremia. Leuk Lymphoma. 2023;64(3):597-604.
Yamamoto S, Ikeda M, Kanno Y, Okamoto K, Okugawa S, Moriya K. Microbiological analysis of infectious lymphocele: Case series and literature review. J Infect Chemother. 2021;27(2):172-8.
Park KH, Jung YJ, Lee HJ, Kim HJ, Maeng CH, Baek SK, et al. Impact of multidrug resistance on outcomes in hematologic cancer patients with bacterial bloodstream infections. Sci Rep. 2024;14(1):15622.
Omori K, Kitagawa H, Takada M, Maeda R, Nomura T, Kubo Y, et al. Fosfomycin as salvage therapy for persistent methicillin-resistant Staphylococcus aureus bacteremia: A case series and review of the literature. J Infect Chemother. 2024;30(4):352-6.
Westgeest AC, Lambregts MMC, Ruffin F, Korn RE, Webster ME, Kair JL, et al. Female Sex and Mortality in Patients with Staphylococcus aureus Bacteremia: A Systematic Review and Meta-analysis. JAMA Netw Open. 2024;7(2):e240473.
Thottacherry E, Cortés-Penfield NW. Evidence of Clinical Impact Supports a New Petition for Medicare Coverage of 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in the Evaluation of Staphylococcus aureus Bacteremia: A Focused Literature Review and Call to Action. Clin Infect Dis. 2022;75(8):1457-61.
Kudo Nagata Y, Sekiya N, Fukushima K, Horiuchi M, Doki N. Ecthyma gangrenosum caused by Staphylococcus aureus in hematological malignancies: Case reports and literature review. Medicine (Baltimore). 2022;101(33):e30070.
Zhan YX, Zhang J, Fan CF, Fan WJ, Xu M. Distribution and drug resistance profiles of pathogens causing bloodstream infection after chemotherapy in children with acute lymphoblastic leukemia. Zhongguo Dang Dai Er Ke Za Zhi. 2022;24(2):176-81.
Finello M, Suasnabar DF, García MJ, Díaz MV, Richetta L, Toranzo A, et al. [Clinical and microbiological characteristics of bloodstream infections in adult neutropenic patients]. Rev Argent Microbiol. 2021;53(3):183-93.
Gaur R, Bao GH. Chemistry and Pharmacology of Natural Catechins from Camellia sinensis as Anti-MRSA Agents. Curr Top Med Chem. 2021;21(17):1519-37.
Peri AM, Edwards F, Henden A, Harris PNA, Chatfield MD, Paterson DL, et al. Bloodstream infections in neutropenic and non-neutropenic patients with haematological malignancies: epidemiological trends and clinical outcomes in Queensland, Australia over the last 20 years. Clin Exp Med. 2023;23(8):4563-73.
Worku M, Belay G, Tigabu A. Bacterial profile and antimicrobial susceptibility patterns in cancer patients. PLoS One. 2022;17(4):e0266919.
Shimabukuro‐Vornhagen A, Böll B, Schellongowski P, Valade S, Metaxa V, Azoulay E, et al. Critical care management of chimeric antigen receptor T‐cell therapy recipients. CA: Canc J Clin 2022;72(1):78-93.
Martinez-Nadal G, Puerta-Alcalde P, Gudiol C, Cardozo C, Albasanz-Puig A, Marco F, et al. Inappropriate empirical antibiotic treatment in high-risk neutropenic patients with bacteremia in the era of multidrug resistance. Clin Infect Dis 2020;70(6):1068-74.
Paprocka P, Durnaś B, Mańkowska A, Król G, Wollny T, Bucki R. Pseudomonas aeruginosa infections in cancer patients. Pathogens 2022;11(6):679.
Tuominen H, Rautava J. Oral microbiota and cancer development. Pathobiology 2021;88(2):116-26.
Li Z, Zhuang H, Wang G, Wang H, Dong Y. Prevalence, predictors, and mortality of bloodstream infections due to methicillin-resistant Staphylococcus aureus in patients with malignancy: systemic review and meta-analysis. BMC infectious diseases 2021;21(1):74.
Abbasi Montazeri E, Khosravi AD, Khazaei S, Sabbagh A. Prevalence of methicillin resistance and superantigenic toxins in Staphylococcus aureus strains isolated from patients with cancer. BMC microbiology 2021;21(1):262.
Macedo F. Bacteremia in Cancer Patients as a Prognostic Factor and the Relationship with Chemotherapy. Med Res Arch 2022;10(12):3501.
Kengne MF, Mbaveng AT, Kuete V. Antibiotic resistance profile of Staphylococcus aureus in cancer patients at Laquintinie hospital in Douala, littoral region, Cameroon. BioMed Res Int 2024;2024(1):5859068.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Mouzma Komal, Haroon Hafeez, Saba Naeem, Summiya Nizamuddin, Muhammad Usman Shabbir (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
